Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor on A1C in patients with Type 1 diabetes is sustained over 52 weeks.
The collaboration aims to drive forward research into treatments for the rare ROS1 gene mutation by gathering tissue samples from patients.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
Monday's dose of additional news of note from around the biopharma world.
Ophthotech has posted negative results from a third phase 3 trial of its wet AMD candidate.
James Mullen has teamed up with colleagues from Biogen to help U.S. biotechs bring drugs to market in Europe.
The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.
Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless…
A 2016 Fierce 15 winner Orchard Therapeutics has taken on Mark Rothera as its new president and chief.
The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.
Roivant Sciences, the parent company of the “Vant” family of biotechs, has secured a massive $1.1 billion investment.